Charles Assenmacher

Dr. Charles Assenmacher

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
GNGiang N. Nguyen
Giang N. Nguyen
JEJohn K. Everett
John K. Everett
Samita KafleSamita Kafle
Samita Kafle
ARAoife M. Roche
Aoife M. Roche
HRHayley E. Raymond
Hayley E. Raymond
DSDenise E. Sabatino
Denise E. Sabatino

20 November 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
BDBenjamin Demarco
Benjamin Demarco
JGJames P. Grayczyk
James P. Grayczyk
EBElisabet Bjanes
Elisabet Bjanes
DRDidier Le Roy
Didier Le Roy
WTWulf Tonnus
Wulf Tonnus
PBPetr Broz
Petr Broz
Gasdermin D (GSDMD) is a pore-forming protein that promotes pyroptosis and release of proinflammatory cytokines. Recent studies revealed that apoptotic caspase-8 directly cleaves GSDMD to trigger pyroptosis. However, the molecular requirements for caspase-8–dependent GSDMD cleavage and the physiological impact of this signaling axis are unresolved. Here, we report that caspase-8–dependent GSDMD cleavage confers susceptibility to tumor necrosis factor (TNF)–induced lethality independently of caspase-1 and that GSDMD activation provides host defense against Yersinia infection. We further demonstrate that GSDMD inactivation by apoptotic caspases at aspartate 88 (D88) suppresses TNF-induced lethality but promotes anti-Yersinia defense. Last, we show that caspase-8 dimerization and autoprocessing are required for GSDMD cleavage, and provide evidence that the caspase-8 autoprocessing and activity on various complexes correlate with its ability to directly cleave GSDMD. These findings reveal GSDMD as a potential therapeutic target to reduce inflammation associated with mutations in the death receptor signaling machinery.

28 July 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
AVAnastasia Velalopoulou
Anastasia Velalopoulou
IKIlias V. Karagounis
Ilias V. Karagounis
GCGwendolyn M. Cramer
Gwendolyn M. Cramer
MKMichele Kim
Michele Kim
GSGiorgos Skoufos
Giorgos Skoufos
Theresa M. BuschTheresa M. Busch
Theresa M. Busch
In studies of electron and proton radiotherapy, ultrahigh dose rates of FLASH radiotherapy appear to produce fewer toxicities than standard dose rates while maintaining local tumor control. FLASH-proton radiotherapy (F-PRT) brings the spatial advantages of PRT to FLASH dose rates (>40 Gy/second), making it important to understand if and how F-PRT spares normal tissues while providing antitumor efficacy that is equivalent to standard-proton radiotherapy (S-PRT). Here we studied PRT damage to skin and mesenchymal tissues of muscle and bone and found that F-PRT of the C57BL/6 murine hind leg produced fewer severe toxicities leading to death or requiring euthanasia than S-PRT of the same dose. RNA-seq analyses of murine skin and bone revealed pathways upregulated by S-PRT yet unaltered by F-PRT, such as apoptosis signaling and keratinocyte differentiation in skin, as well as osteoclast differentiation and chondrocyte development in bone. Corroborating these findings, F-PRT reduced skin injury, stem cell depletion, and inflammation, mitigated late effects including lymphedema, and decreased histopathologically detected myofiber atrophy, bone resorption, hair follicle atrophy, and epidermal hyperplasia. F-PRT was equipotent to S-PRT in control of two murine sarcoma models, including at an orthotopic intramuscular site, thereby establishing its relevance to mesenchymal cancers. Finally, S-PRT produced greater increases in TGFβ1 in murine skin and the skin of canines enrolled in a phase I study of F-PRT versus S-PRT. Collectively, these data provide novel insights into F-PRT-mediated tissue sparing and support its ongoing investigation in applications that would benefit from this sparing of skin and mesenchymal tissues.Significance: These findings will spur investigation of FLASH radiotherapy in sarcoma and additional cancers where mesenchymal tissues are at risk, including head and neck cancer, breast cancer, and pelvic malignancies.

1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JLJinmin Lee
Jinmin Lee
DLDaniel K. Lundgren
Daniel K. Lundgren
XMXuming Mao
Xuming Mao
SMSilvio Manfredo-Vieira
Silvio Manfredo-Vieira
SNSelene Nunez-Cruz
Selene Nunez-Cruz
APAimee S. Payne
Aimee S. Payne
Desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) expressing the pemphigus vulgaris (PV) autoantigen DSG3 fused to CD137-CD3ζ signaling domains, represent a precision cellular immunotherapy approach for antigen-specific B cell depletion. Here, we present definitive preclinical studies enabling a first-in-human trial of DSG3-CAART for mucosal PV. DSG3-CAART specifically lysed human anti-DSG3 B cells from PV patients and demonstrated activity consistent with a threshold dose in vivo, resulting in decreased target cell burden, decreased serum and tissue-bound autoantibodies, and increased DSG3-CAART engraftment. In a PV active immune model with physiologic anti-DSG3 IgG levels, DSG3-CAART inhibited antibody responses against pathogenic DSG3 epitopes and autoantibody binding to epithelial tissues, leading to clinical and histologic resolution of blisters. DSG3 autoantibodies stimulated DSG3-CAART IFN-γ secretion and homotypic clustering, consistent with an activated phenotype. Toxicology screens using primary human cells and high-throughput membrane proteome arrays did not identify off-target cytotoxic interactions. These preclinical data guided the trial design for DSG3-CAART and may help inform CAART preclinical development for other antibody-mediated diseases.

22 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
QZQian Zhang
Qian Zhang
MHMorgan E. Hresko
Morgan E. Hresko
LPLora K. Picton
Lora K. Picton
LSLeon Su
Leon Su
MHMichael J. Hollander
Michael J. Hollander
MMMichael C. Milone
Michael C. Milone
A human IL-2 and IL-2Rβ orthogonal cytokine-receptor pair enables a tunable approach to enhancing CAR T cell engraftment and antitumor efficacy.

6 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KCKaiwen W. Chen
Kaiwen W. Chen
BDBenjamin Demarco
Benjamin Demarco
SRSaray Ramos
Saray Ramos
RHRosalie Heilig
Rosalie Heilig
MGMichiel Goris
Michiel Goris
PBPetr Broz
Petr Broz
Significance: Pathogenic bacteria subvert host-defense mechanisms by injecting effector proteins into target cells to inhibit NF-κB and MAPK signaling. Detection of such effector proteins, such as YopJ from pathogenic Yersinia , activates RIPK1 and caspase-8–dependent cell death that promotes antibacterial defense. While recent studies demonstrate that caspase-8 cleaves the pore-forming protein gasdermin D to promote anti- Yersinia defense, whether RIPK1 activates other substrates is unclear. Here, we demonstrate that RIPK1 activates gasdermin D in macrophages and the related gasdermin E in neutrophils to promote host defense. Neutralization of IL-1β in vivo promoted host susceptibility to Yersinia infection in wild-type, but not Gsdme −/− , animals, revealing an unexpected role for gasdermin E in IL-1β secretion during bacterial infection.